Generation of a KSCBi005-A-5(TLR8KO-A10) homozygous knockout human induced pluripotent stem cell line using CRISPR/Cas9

Han, Heon-Seok; Seo, Hyang-Hee; Kim, Jung-Hyun

doi:10.1016/j.scr.2019.101561

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many CRISPR/Cas9 systems target different viral genes, including tat, 27 env, 28 vif, 29 gag, 30 nef, 31 and reverse transcriptase 32 . Moreover, host cellular cofactors CCR5, 33 CD4, 34 and NFkB 35 have been shown to be effective in inhibiting HIV replication.…”

Section: Introductionmentioning

confidence: 99%

Intravaginal delivery for CRISPR–Cas9 technology: For example, the treatment of HPV infection

Zhen

Chen

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

The increasing incidence of sexually transmitted diseases in women, including human papillomavirus (HPV) infection, has led to the need to develop user‐friendly potential prevention methods. At present, although there are several therapeutic parts, none of them has a preventive effect, but they are only limited to providing patients with symptom relief. Researchers have now recognized the need to find effective local preventive agents. One of the potential undiscovered local fungicides is the vaginal delivery of CRISPR/Cas9. CRISPR/Cas9 delivery involves silencing gene expression in a sequence‐specific manner in the pathogenic agent, thus showing microbicidal activity. However, vaginal mucosal barrier and physiological changes (such as pH value and variable epithelial thickness in the menstrual cycle) are the main obstacles to effective delivery and cell uptake of CRISPR/Cas9. To enhance the vaginal delivery of CRISPR/Cas9, so far, nano‐carrier systems such as lipid delivery systems, macromolecular systems, polymer nanoparticles, aptamers, and cell‐penetrating peptides have been extensively studied. In this paper, various nano‐carriers and their prospects in the preclinical stage are described, as well as the future significance of CRISPR/Cas9 vaginal delivery based on nano‐carriers.

show abstract

Section: Introductionmentioning

confidence: 99%

Intravaginal delivery for CRISPR–Cas9 technology: For example, the treatment of HPV infection

Zhen

Chen

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

Application of the CRISPR/Cas9 System to Study Regulation Pathways of the Cellular Immune Response to Influenza Virus

Prokhorova

Жукова

Lemza

et al. 2022

Viruses

View full text Add to dashboard Cite

Influenza A virus (IAV) causes a respiratory infection that affects millions of people of different age groups and can lead to acute respiratory distress syndrome. Currently, host genes, receptors, and other cellular components critical for IAV replication are actively studied. One of the most convenient and accessible genome-editing tools to facilitate these studies is the CRISPR/Cas9 system. This tool allows for regulating the expression of both viral and host cell genes to enhance or impair viral entry and replication. This review considers the effect of the genome editing system on specific target genes in cells (human and chicken) in terms of subsequent changes in the influenza virus life cycle and the efficiency of virus particle production.

show abstract

Generation of a KSCBi005-A-5(TLR8KO-A10) homozygous knockout human induced pluripotent stem cell line using CRISPR/Cas9

Cited by 2 publications

References 5 publications

Intravaginal delivery for CRISPR–Cas9 technology: For example, the treatment of HPV infection

Intravaginal delivery for CRISPR–Cas9 technology: For example, the treatment of HPV infection

Application of the CRISPR/Cas9 System to Study Regulation Pathways of the Cellular Immune Response to Influenza Virus

Contact Info

Product

Resources

About